EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay

Alan H B Wu, Simon A Mahler, Stacey L House, Saeed A Jortani, Michael H Creer, Kristin L Rising, Jason J Bischof, Chad Crystal, Gary F Headden, Fred S Apple, Nicholas E Harrison, Andrew C Meltzer und 8 weitere

The Journal of Applied Laboratory Medicine · 05.01.2026 · 11 (1) · 98-112

DOI: 10.1093/jalm/jfaf152 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 28.10.2025. Verfasst von Alan H B Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University of California, San Francisco, CA, United States. Hauptthemen laut MEDLINE: Troponin I, Myocardial Infarction, Point-of-Care Systems, Acute Coronary Syndrome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Point of Care, Abbott Laboratories.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-sensitivity cardiac troponin (hs-cTn) assays performed in the central laboratory have long turnaround times. This study evaluates the clinical performance of a novel bedside point-of-care (POC) hs-cTnI assay (i-STAT® hs-TnI) to aid in the diagnosis of myocardial infarction (MI).

Methods

A prospective multisite cohort study involving emergency department (ED) patients with symptoms suggestive of acute coronary syndrome was conducted at 28 sites across the United States. Serial whole blood samples were collected at 0–1 h and >1–3 h from ED presentation. Primary outcome was MI or non-MI. Sensitivity, specificity, and negative predictive value (NPV) for MI were calculated with 97.5% lower confidence limits (LCL) using the female, male, and overall 99th percentile upper reference limit (URL, 13, 28, and 21 ng/L, respectively). Post hoc analysis was also conducted for initial measurements below the limit of quantification (LoQ, 2.9 ng/L) and <5.0 ng/L.

Results

The cohort included 3582 patients, median age 59 y, 64% female. MI incidence was 8.6%. Sensitivity and specificity at >1–3 h were 96.6% (LCL 91.7%) and 82.1% (80.2%) using the female URL; 90.7% (LCL 84.1%) and 83.9% (LCL 81.4%) using the male URL; and 92.4% (LCL 88.3%) and 85.6% (LCL 84.2%) using the overall URL. NPVs for MI of initial hs-cTnI measurements <LoQ and <5.0 ng/L were 99.8% (LCL 99.2%) and 99.8% (LCL 99.4%) respectively.

Conclusions

The whole blood POC i-STAT hs-TnI assay demonstrated performance characteristics similar to other hs-cTn assays and achieved high sensitivity and NPV for initial measurements <LoQ and <5.0 ng/L. ClinicalTrials.gov Registration Number NCT05629572.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Troponin IMyocardial InfarctionPoint-of-Care SystemsAcute Coronary SyndromeHumansMaleFemaleMiddle AgedProspective StudiesAgedSensitivity and SpecificityBiomarkersEmergency Service, HospitalUnited StatesPredictive Value of TestsPoint-of-Care Testing

Substanzen

Troponin IBiomarkers

Autor:innen und Institutionen

  • Department of Laboratory Medicine, University of California, San Francisco, CA, United States.
  • Departments of Emergency Medicine, Epidemiology and Prevention, and Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
  • Department of Emergency Medicine, Washington University School of Medicine, St. Louis, MO, United States.
  • Department of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, KY, United States.
  • Department of Laboratory Medicine and Pathology, Penn State University Hershey Medical Center, Hershey, PA, United States.
  • Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, United States.

Förderung

  • Abbott Point of Care
  • Abbott Laboratories

Zitieren

APA

Wu, A. H. B., Mahler, S. A., House, S. L., Jortani, S. A., Creer, M. H., Rising, K. L., Bischof, J. J., Crystal, C., Headden, G. F., Apple, F. S., Harrison, N. E., Meltzer, A. C., Baca, J. T., Tiffany, B., Sochor, M., Pentecostes, G. U., Di Tullio, K. P., Gupta, M. S., Singer, A. J., & Januzzi, J. L. (2026). Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay. The Journal of Applied Laboratory Medicine, 11(1), 98-112. https://doi.org/10.1093/jalm/jfaf152

Vancouver

Wu AHB, Mahler SA, House SL, Jortani SA, Creer MH, Rising KL, et al. Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay. The Journal of Applied Laboratory Medicine. 2026;11(1):98-112. doi:10.1093/jalm/jfaf152

BibTeX
@article{Wu2026,
  author = {Wu, Alan H B and Mahler, Simon A and House, Stacey L and Jortani, Saeed A and Creer, Michael H and Rising, Kristin L and Bischof, Jason J and Crystal, Chad and Headden, Gary F and Apple, Fred S and Harrison, Nicholas E and Meltzer, Andrew C and Baca, Justin T and Tiffany, Brian and Sochor, Mark and Pentecostes, Grace U and Di Tullio, Katrina P and Gupta, Manish S and Singer, Adam J and Januzzi, James L},
  title = {Clinical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {98--112},
  doi = {10.1093/jalm/jfaf152}
}
Kostenlos starten →